| 摘要 |
An agent for preventing or treating hemorrhage tendency comprising IL-6 as an active ingredient is presented. The in vivo administration of IL-6 enhances both platelet function and vascular endothelial cell function, to improve predispositions to bleeding disorder, thereby promoting hemostatic ability. That is, IL-6 has activity to efficiently treat hemorrhage tendency in vivo, and since it is an inherently natural bioactive substance, it is useful as an excellent phermaceutical composition for treating or preventing hemorrhage tendency. Thus, IL-6 is useful for treating the hemorrhage tendency attributable to the bone marrow supression occurring after the chemotherapy of cancer or after the radiotherapy of cancer, the hemorrhage tendency occurring after bone marrow transplantation, the hemorrhage tendency of aplastic anemia, and the hemorrhage tendency in idiopathic thrombocytopenic purpura.
|
